For information on this past event please contact Meetings Management

PROVISIONAL CONFERENCE PROGRAM

Wednesday 17th November 2004

08.55-09.00
Welcome & Opening Remarks by DNA VACCINES 2004 Conference Chairman:
Professor David B. Weiner (University of Pennsylvania, USA)

SESSION 1:
Opening Plenary Session A

Moderator:
David Weiner (University of Pennsylvania, USA)

09.00-09.30
KEYNOTE:
‘Vaccination and immunological memory’
Antonio Lanzavecchia (Institute for Research in Biomedicine, Bellinzona, Switzerland)

09.30-10.00
KEYNOTE:
‘Regulation of T-cell mediated immunity’
Abul Abbas (University of California, San Francisco, USA)

10.00-10.30
KEYNOTE:
‘Genetic vaccination, central memory T cells and protection’
Maurizio Zannetti (University of California, San Diego, USA)

10.30-11.00
Coffee Break & Posters

SESSION 2:
Plenary Session B

Moderator:
Eyal Raz (University of California, San Diego, USA)

11.00-11.30
‘Antigen immunostimulatory conjugate (AIC): A potent alternative for a DNA vaccine’
Eyal Raz (University of California, San Diego, USA)

11.30-12.00
‘Cellular and molecular studies of B cells exhibiting reverse somatic mutation throughout life’
Constantin Bona (The Mount Sinai School of Medicine, New York, USA)

12.00-12.30
‘Insertional mutagenesis by plasmid DNA and adenovirus-vectored vaccines’
Brian Ledwith (MERCK, West Point, USA)

12.30-13.00
‘Discovering HIV-1 envelope immunogens: Use of DNA shuffling and in vivo screening’
Robert Whalen (Maxygen Inc., USA)

13.00-14.00
Lunch & Posters

SESSION 3:
IMPROVING DNA VACCINES

Moderator:
Ralf Wagner (University of Regensburg, Germany)

14.00-14.30
‘Scalable replication – incompetent adenovirus-based vaccines against malaria and HIV: avoidance of pre-existing immunity to adenoviruses’
Menzo Havenga (Crucell, The Netherlands)

14.30-15.00
‘Complexing plasmid DNA and cationic peptides: a novel multivalent combination vaccine for T cells’
P. Riedl, R. Schirmbeck, J. Reimann (University of Ulm, Germany)

15.00-15.30
‘HIV-vaccines: Novel strategies to improve vaccine safety and efficacy’
Ralf Wagner (University of Regensburg, Germany)

15.30-16.00
’Improving polyvalent HIV vaccines for human study’
Shan Lu (University of Massachusetts Medical School, USA)

16.00-16.20
Tea Break & Posters

SESSION 4:
IMMUNOLOGY/ADJUVANTS/FORMULATION/DELIVERY

Moderator:
Britta Wahren (Karolinska Institute, Stockholm, Sweden)

16.20-16.50
‘Molecular adjuvants improve cellular immune potency of DNA vaccines in non-human primates’
David Weiner (University of Pennsylvania, USA)

16.50-17.20
‘Polymeric delivery system in human clinical trials for cervical dysplasia’
Mary Lynn Hedley (ZYCOS Inc., USA)

17.20-17.40
‘Successful parallel development and integration of a plasmid-based biologic, container/closure system and delivery device’
Henry Hebel, Ruxandra Draghia-Akli, Heather Attra, Robert Carpenter, Amir Khan, Doug Kern (ADViSYS Inc., Texas, USA)

17.40-18.00
‘ORT-VAC: antibiotic-free plasmid selection and stable maintenance for vaccine delivery using live bacteria’
R. Cranenburgh (Cobra Biomanufacturing PLC, Keele, UK)

18.00-18.20
‘Use of linear, minimalistic (MIDGE™) vectors in DNA vaccination’
M. Timon et al. (Mologen Molecular Medicines SL, Madrid, Spain)

18.20-18.40
‘IL-10 is required for induction but not effector functions of autoreactive (insulin-B specific), IL-4 dependent regulatory cells’
V. Verhasselt, M. von Herrath, E. Rodrigo, A. Bot, S. Bot, A. Juedes (La Jolla Institute for Allergy and Immunology, San Diego, USA)

18.40-19.00
‘Particle-mediated epidermal delivery of DNA vaccines: Pre-clinical and clinical update’
John Beadle (PowderMed, UK)

19.00-20.00
Welcome Reception & Poster Session A